Abstract:We describe an in vivo mutagenesis model that utilizes reverse mutation and forward mutation at the endogenous Aprt locus. Reverse mutation provides an in situ method for detecting environments or agents that cause point mutations. Forward mutation detects large chromosomal events, including mitotic recombination, chromosome loss, and large multilocus deletion, all of which can lead to loss of heterozygosity. Detection of reverse mutation in vivo is based on the differential capacity of Aprt and Aprt cells to sequester radiolabeled adenine by catalyzing its conversion to adenosine monophosphate with subsequent incorporation into nucleic acids. Cells lacking APRT activity cannot accumulate exogenously administered, tagged adenine, whereas Aprt+ cells can and will thereby become marked. Thus, genetically modified mice with mutant but revertible Aprt alleles should be a useful vehicle for in situ detection of mutagenic activity in the whole animal. the feasibility of this model has been illustrated, first, by showing that APRT-deficient mice are viable and, second, by demonstrating that the minority of Aprt+ cells within a chimeric tumor growing in an Aprt+ mouse can be selectively labeled following IP injection of [14C]-adenine and can be identified by autoradiography. Forward mutation, detected by growth in selective medium of primary cells derived from Aprt+/- heterozygous mice, provides on independent estimate of in vivo mutation frequency. The frequency with which Aprt colonies arise provides a measure of the frequency of Aprt(-)-negative cells in the tissue at that point in time. Culture of skin fibroblasts in 2,6-diaminopurine (DAP) produced Aprt+ colonies with a frequency of about 10(-4). This frequency is similar to that found for human T lymphocytes from individuals heterozygous at the Aprt locus. In both cases, the majority of mutagenic events involved allele loss. Polymerase chain reaction with linked polymorphic microsatellites on mouse chromosome 8 demonstrated that allele loss was mediated mostly by mitotic recombination, as was the case for human T lymphocytes. The high frequency of mitotic recombination and allele loss at a neutral locus has significant implications for the process of tumorigenesis and argues that spontaneous or induced mitotic recombination may play a causal role in the progression to cancer.

High Frequency in Vivo Loss of Heterozygosity is Primarily a Consequence of Mitotic Recombination.

Mitotic Recombination is the Predominant Cause of in Vivo Loss of Heterozygosity in T Lymphocytes of APRT Heterozygotes

Complex chromosomal mechanisms lead to APRT loss of heterozygosity in heteroploid cells.

Loss of Heterozygosity Analysis in A Human Fibrosarcoma Cell Line

Mitotic Recombination Produces The Majority Of Recessive Fibroblast Variants In Heterozygous Mice

In Vivo Loss of Heterozygosity in T-cells of B6C3F1 Aprt(+/-) Mice.

Loss of Heterozygosity on Chromosome 3p in Thyroid Tumors

Loss of Heterozygosity on Chromosome 3p in Breast Cancer and Precancerous Lesion

Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma

Massive interstitial copy-neutral loss-of-heterozygosity as evidence for cancer being a disease of the DNA-damage response

Loss of Heterozygosity in Human Aberrant Crypt Foci (ACF), a Putative Precursor of Colon Cancer.

Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities

Other Transgenic Mutation Assays: APRT: A Versatile in Vivo Resident Reporter of Local Mutation and Loss of Heterozygosity

Pretransplant HLA Mistyping in Diagnostic Sample of a T-ALL Patient Due to Loss of Heterozygosity in the Major Histocompatibility Complex.

Loss of heterozygosity in thyroid hormone receptor beta in invasive breast cancer.

Detailed Deletion Mapping of Loss of Heterozygosity on 22q13 in Sporadic Colorectal Cancer

Loss of Heterozygosity and Its Correlation with Expression Profiles in Subclasses of Invasive Breast Cancers

High-resolution Single-Nucleotide Polymorphism Array and Clustering Analysis of Loss of Heterozygosity in Human Lung Cancer Cell Lines.

Chromosome Instability Contributes To Loss Of Heterozygosity In Mice Lacking P53

Loss of Heterozygosity of Chromosome 20 in Sporadic Colorectal Cancer.

Refined Mapping of Loss of Heterzygosity on Chromosome 1 in Sporadic Colorectal Carcinoma